Introduction
============

A large body of studies has shown that endothelial growth factors involved in neo-angiogenesis are largely responsible for or associated with tumor progression and spread. The activation of endothelial cells during tumorigenesis has been defined as the result of the locoregional imbalance between pro-angiogenic and anti-angiogenic factors \[[@B1]\].

Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are two heparin-binding molecules with potent angiogenic properties both *in vivo*and *in vitro.*VEGF comprises four alternative splicing variants that exert a similar activity on endothelial cell proliferation, on *in vitro*migration and on *in vivo*permeability. VEGF-soluble proteins bind to two specific tyrosine-kinase receptors, VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR), which are expressed preferentially in endothelial cells. bFGF is the most widely investigated member of the fibroblast growth factor family. In normal tissue bFGF is present in basement membranes and in the subendothelial extracellular matrix of blood vessels, and stays membrane-bound as long as there is no signal peptide. In particular, it has been hypothesized that, during both wound healing of normal tissues and tumor development, the action of heparan sulfate degrading enzymes activates bFGF, thus mediating the formation of new blood vessels \[[@B2],[@B3]\].

Higher VEGF and bFGF levels have been found in the serum and urine of patients with different tumor types than in healthy individuals \[[@B4]-[@B7]\], and in the serum of patients with metastatic disease than in those with localized disease \[[@B8],[@B9]\]. Some studies in patients with breast cancer have investigated the potential of serum VEGF and bFGF levels for diagnostic purposes \[[@B5]-[@B7],[@B9],[@B10]\] or for monitoring the clinical course of disease \[[@B11]-[@B14]\]. A decrease in VEGF serum levels \[[@B5],[@B8],[@B15]\] and a tendency of VEGF to increase after breast cancer surgery \[[@B16]\] have been reported. These controversial results could perhaps be ascribed to the lack of standardization of the pre-analytical phase related to the serum separation time and the clotting temperature, which can influence platelet activation and, consequently, compromise reliability and reproducibility of the determinations \[[@B15],[@B17]-[@B19]\].

Very little information is available for bFGF with respect to platelet activation \[[@B20],[@B21]\]. There is some evidence of the potential of its level in serum for disease monitoring \[[@B11]-[@B13]\], and only one group has investigated its role in the early detection of breast cancer \[[@B6]\].

In the present study, we analyzed the relationship between the expression of VEGF and bFGF in breast cancer cells and the corresponding serum levels in individual patients. We also aimed to define the potential of serum levels of the two growth factors as diagnostic markers in a case--control study.

Materials and methods
=====================

Case series
-----------

The study was conducted on healthy women and on patients with breast cancer. Most of the patients were recruited from individuals attending the Screening Program run by the Prevention Unit of the Medical Oncology Department of Pierantoni Hospital, and all of the women were older than 50 years of age (range, 51--92 years; median, 67 years). All patients had histologically confirmed breast cancer.

The control group comprised women who were free from any disease associated with an increased angiogenic activity such as diabetic retinopathy, heart disease or lung disease, which could affect VEGF levels and, possibly, bFGF levels. Healthy women ranged in age from 51 to 77 years, with a median age of 60 years.

The study was examined and approved by the Ethics Committee of the Local Health and Social Services (Azienda USL, Forlì) in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Written informed consent was obtained from all the women participating in the study.

Growth factors were determined in the tumor and in the serum. Specifically, VEGF and bFGF expression was determined in 62 and 63 tumor samples, respectively. Serum VEGF and bFGF levels were determined in 54 and 65 healthy women, and in 69 and 73 breast cancer patients, respectively.

Immunohistochemical determinations
----------------------------------

Tumor tissue removed during surgery was fixed in neutral buffered 10% formalin and embedded in paraffin. Four-micrometer sections of the histologically confirmed tumor samples were mounted on positive-charged slides (BioOptica, Milan, Italy), deparaffinized with xylene, rehydrated, and the endogenous peroxidase activity blocked by 3% hydrogen peroxide solution.

VEGF expression was determined using a polyclonal antibody that specifically reacts with isoforms 121, 165, 189, and 206 (Biogenex, San Ramon, CA, USA). bFGF expression was determined using a monoclonal antibody that reacts with the bFGF 18--24 kDa isoforms (Transduction Laboratories, Lexington, KY, USA). Expression of the estrogen receptor (ER) and of the progesterone receptor (PgR) was determined using 1D5 and 1A6 monoclonal antibodies, respectively (Biogenex).

VEGF, bFGF, ER, and PgR antigen retrieval was performed by microwaving at 75 W for 15 min in 10 mM citrate buffer (pH 6.0) followed by cooling at room temperature for at least 20 min. The sections were then treated for non-specific binding with 3% bovine serum albumin in PBS for 20 min, after which they were incubated for 1 hour at room temperature with prediluted polyclonal anti-VEGF antibody or monoclonal anti-ER and anti-PgR antibodies or anti-bFGF monoclonal antibody diluted 1:100 in PBS. Positive control slides (HL-60, K562, and HeLa tumor cell lines for VEGF and bFGF, and normal breast tissue for ER and PgR) were stained in parallel with the antibodies. The sections were washed with PBS, incubated with universal biotinylated secondary antibody, rinsed in PBS, and incubated with streptavidin--peroxidase conjugate (LSAB+kit; DAKO Corporation, Carpinteria, CA, USA) for 15 min. Sections were rinsed again in PBS, and antibody binding was detected by staining with diaminobenzidine/hydrogen peroxidase chromogen solution (DAB+liquid substrate--chromogen solution; DAKO Corporation). Finally, sections were rinsed in deionized water, were counterstained blue by Mayer\'s Hemalum, and were mounted in Eukitt (Bio-Optica).

VEGF and bFGF expression was evaluated at a light microscope (200 ×) by two independent observers (AMG and LM). Immunoreactivity was expressed as the percentage of the immunopositive area in relation to the total area of invasive neoplastic tissue of the whole section. ER and PgR analysis was performed by an image analyzer system (CAS 200; Becton Dickinson, San Jose, CA, USA) and expressed as already described.

Immunoassay
-----------

Peripheral venous blood was collected in sterile test tubes (Vacutainer System; Becton Dickinson), left to coagulate at 4°C for 30 min, centrifuged at 2000 × *g*for 10 min, and then stored in aliquots at -70°C for a maximum of 1 month.

VEGF and bFGF levels were determined using a quantitative sandwich enzyme immunoassay technique (Quantikine; R&D System, Minneapolis, MN, USA) and all samples were tested in duplicate. Briefly, 100 μl assay diluent and 100 or 150 μl serum sample for VEGF and bFGF, respectively, or scalar concentrations of VEGF (15.6, 31.2, 62.5, 125, 250, 500, 1000 and 2000 pg/ml) and bFGF (0.5, 1, 2, 4, 8, 16, 32 and 64 pg/ml) were added to each well of a microtiter plate precoated with mouse antihuman VEGF or mouse antihuman bFGF monoclonal antibody. Plates were incubated at room temperature for 2 or 3 hours for VEGF and bFGF, respectively. The wells were then washed to remove unbound VEGF or bFGF, supplemented with 200 μl enzyme-linked anti-VEGF or anti-bFGF polyclonal antibodies and incubated for 2 hours at room temperature. The wells were washed again, supplemented with antibody-linked enzyme substrates, and left for 25 min at room temperature. For bFGF assay only, an amplifier solution was added and the reaction was prolonged for 25 min.

After the addition of 50 μl stop reagent (2 M sulphuric acid), the color intensity in each well was measured at 450 nm for VEGF and at 490 nm for bFGF using a spectrophotometer (Medical System, Genoa, Italy). The optical density found in the serum samples was compared with a standard curve of VEGF and bFGF concentrations and was quantified. The coefficient of linearity, which shows the linear correlation between measured absorbance and known amounts of standards, was at least 0.9 for both bFGF and VEGF. The minimum detectable concentration ranged from 0.05 to 0.56 pg/ml for bFGF and was less than 9 pg/ml for VEGF, as quoted by the manufacturer.

With regard to intra-assay reproducibility, the determinations of growth factor serum levels were performed in duplicate and were repeated when the coefficient of variation (CV) exceeded 15%. The highest disagreement between the pair values was observed for low levels of the growth factors. Overall, the CV was less than 15% in 85% of cases for either VEGF (105 out of 123 samples) or bFGF (117 out of 138 samples). The CV was less than 10% in 76% of cases for VEGF and in 68% of cases for bFGF.

Assessment of interassay reproducibility was made by calculating the CV for growth factor levels of serum samples from five individuals run in quintuplicate. The CV for VEGF determinations ranged from 4.9% to 9.5%, and that for bFGF from 3% to 13.3%. In consideration of the low serum concentrations of bFGF and of the fact that the tests were carried out manually, we considered a CV higher than 10% but lower than 15% acceptable.

Statistical analysis
--------------------

Nonparametric ranking statistics (median test) were used to analyze the relationship between the percentage of positive tumor cells and the serum levels of VEGF and bFGF, considered as continuous variables, and patient characteristics. Spearman\'s correlation coefficient was used to investigate the relationship between the two markers in the serum or in the tumor. The relation between VEGF and bFGF serum levels and the presence of breast cancer in the case--control study was analyzed using the median test.

The most accurate cut-off value capable of discriminating between healthy women and cancer patients, in the absence of internationally accepted cut-off values for serum bFGF and VEGF concentrations, was identified using a receiver operating characteristic (ROC) curve analysis. In the ROC curve the true positive rates (sensitivity) were plotted against the false positive rates (specificity) for all classification points. Ninety-five percent confidence intervals were calculated for sensitivity and specificity values.

Results
=======

Basic studies
-------------

### Vascular endothelial growth factor

The percentage of the tumor immunopositive areas ranged from 5 to 100% (median, 65%) and the immunoreaction was limited to the cytoplasm. Tumor immunopositivity was not related to patient age, to tumor size, or to lymph node involvement. Tumor immunopositivity was significantly higher in ductal tumor than in other histologies and, unexpectedly, higher in ER-positive and grade 1--2 tumors than in ER-negative or grade 3 tumors (Table [1](#T1){ref-type="table"}).

Serum levels ranged from 22.7 to 953.5 pg/ml (median, 192.7 pg/ml) and were not related to any biological or pathological variable.

### Basic fibroblast growth factor

The percentage of the immunopositive areas varied greatly in the different tumors, from a total absence to positivity over the whole tumor area. In the majority of cases (84%) positivity was limited to the cytoplasm, and in a minority (16%) it was observed in both the nucleus and the cytoplasm of the tumor cells. Moreover, in the contiguous macroscopically normal mammary epithelium, positivity was limited to the cell nuclei of the basal layer of mammary ducts. bFGF tumor expression was similar in the subgroups defined by different clinical, pathological, and hormonal characteristics (Table [2](#T2){ref-type="table"}).

Serum levels ranged from 0.3 to 26.6 pg/ml (median, 2.3 pg/ml) and once again values were not statistically different as a function of different pathological and biological variables.

A linear correlation was observed between VEGF and bFGF expression in individual tumors (*P*= 0.001) and between serum levels (*P*= 0.038) in individual patients (Table [3](#T3){ref-type="table"}). No correlation was observed between tumor cell expression and the corresponding serum level for either growth factor.

Case--control study
-------------------

VEGF serum levels in healthy women ranged from 0 to 707.6 pg/ml, with a median value of 145.7 pg/ml. bFGF serum levels in healthy women varied from 0 to 5.7 pg/ml, with a median value of 0.4 pg/ml.

A considerable overlapping of serum VEGF levels between healthy women and breast cancer patients was observed, and median values were not significantly different (*P*= 0.055). Values in cancer patients exceeded the highest value (707.6 pg/ml) detected in healthy women in only two (2.8%) cases (Fig. [1a](#F1){ref-type="fig"}).

A partial overlapping of bFGF serum levels in healthy women and in breast cancer patients was also observed, but the difference between the median values of the two subgroups was significantly different (*P*\< 0.001) (Fig. [1b](#F1){ref-type="fig"}). Moreover, all values equal to or higher than 6.0 pg/ml (8/8) referred to cancer patients, while the total absence of bFGF in the serum (27/27) was only observed in healthy women.

The ROC curve did not highlight any acceptable concentration of serum VEGF in terms of either sensitivity or specificity (Fig. [2a](#F2){ref-type="fig"}). Conversely, when calculated using serum bFGF values of healthy women and of breast cancer patients (Fig. [2b](#F2){ref-type="fig"}), the ROC curve identified a concentration of 1.0 pg/ml, with an 84.9% sensitivity and a 63.1% specificity, as the best discriminant (Table [4](#T4){ref-type="table"}). For patients older than 70 years of age, a similar sensitivity (77.8%) and a higher specificity (78.6%) were observed.

Discussion
==========

Information on the clinical relevance of VEGF expression and bFGF expression in breast cancer patients is inconclusive. In addition to positive data \[[@B22]-[@B24]\] negative results on the prognostic relevance have been reported \[[@B25]\], particularly when their role was assessed according to internationally accepted guidelines in a large series of node-negative breast cancer patients not treated with any type of systemic therapy \[[@B26]\]. To exert their potent angiogenic effect, however, these growth factors have to be secreted by tumor cells, and altered amounts are therefore expected to be present in the blood of patients.

In the present study, we found a correlation in individual patients between the expression of VEGF and bFGF in tumor cells as well as between their levels in serum, but not between the expression in tumor cells and the serum concentration of either growth factor. It is also worthy of note that bFGF expression in tumor cells was not correlated with any conventional pathological or biological variable of prognostic relevance and that VEGF expression was not significantly related to tumor size or to nodal involvement. Furthermore, VEGF expression was significantly higher in ductal tumors and, paradoxically, inversely related to the grade and the ER level, as already observed by other authors \[[@B15]\]. It can therefore be concluded that the expression of these growth factors is not closely related to tumor growth and progression, which could justify the negative results on their prognostic relevance.

The question now arises: what point in the preclinical or the clinical tumor lifespan do cancer cells produce angiogenic factors, and when do these become determinant in stimulating and supporting tumor growth? Preliminary but suggestive data have shown that VEGF serum levels of patients with *in situ*breast carcinoma are comparable with, if not higher than, those detected in the sera of women with primary invasive breast cancer \[[@B7],[@B9]\]. This finding was also observed for serum levels of bFGF in a small preliminary series of patients with *in situ*carcinoma (data not shown). This suggests that the secretion of angiogenic factors might occur in the early phases and might play an important role in preclinical tumor life \[[@B27]\].

To verify the potential of VEGF and bFGF serum levels as noninvasive diagnostic markers, we performed a case--control study. Our results seem to indicate that VEGF serum levels are not useful as a diagnostic tool for breast cancer due to the considerable overlapping of the sets of values observed in healthy women and in patients, in agreement with some previous results \[[@B28],[@B29]\] and in contrast with others \[[@B7],[@B9]\]. We would like to underline, however, that our data were obtained under strict standardized conditions for the serum separation time and the clotting temperature, both important pre-analytical aspects, since VEGF levels in the serum are known to be largely platelet derived \[[@B17]-[@B19],[@B30]-[@B33]\]. Our evidence is supported by the negative results on the clinical relevance of VEGF detected in nipple aspirate fluid \[[@B27]\], independent of any platelet activation.

Positive results were conversely observed for bFGF serum levels that, although partially overlapping in healthy women and in patients, showed statistically different median values in the two groups. Moreover, a total absence of bFGF in serum was observed exclusively in healthy women, while values equal to or higher than 6 pg/ml were found only in breast cancer patients.

The ROC analysis identified a cut-off serum concentration with a high sensitivity and a good specificity to identify breast cancer patients. An age-based subgroup analysis showed that serum values of patients older than 70 years of age contributed largely to this sensitivity and specificity.

Our results are in agreement with those reported by other authors who brought to light the importance of bFGF serum levels in discriminating between healthy women and breast cancer patients. These studies were conducted using a nonstandardized inhouse enzyme immunoassay methodology \[[@B6]\] on a heterogeneous series of patients \[[@B11]\] or on small case--control subgroups \[[@B30]\]. The results from the present study, which was conducted on a large, prospectively planned case--control series, in which all the patients had operable tumors and in which all determinations were carried out under strict standardized and quality-controlled procedures, repropose the usefulness of the bFGF serum level for breast cancer detection.

The determination of serum bFGF represents a simple, inexpensive and noninvasive approach, also when compared with recently proposed nipple aspiration \[[@B27]\], and would seem to be indicated mainly for women older than 70 years of age to whom mammograms and clinical screening are not routinely offered. Moreover, bFGF would seem to have a higher accuracy than other biomarkers such as carcinoembryonic antigen or cancer antigen 15.3, which were proposed for cancer diagnosis some years ago and, albeit not fully validated \[[@B34]\], are now used for monitoring purposes.

Conclusion
==========

The bFGF serum level is associated with the presence of breast cancer. Its usefulness for the early detection of sporadic cancer, within screening programs, and in monitoring members of high-risk breast cancer families warrants a prospective validation in a confirmatory study.
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![Box plots of **(a)**vascular endothelial growth factor (VEGF) and **(b)**basic fibroblast growth factor (bFGF) serum levels. The lower boundary of the box is the 25th percentile and the upper boundary is the 75th percentile. The bold line inside the box represents the median. \* Cases with values more than 1.5 box lengths from the upper or lower edge of the box (extreme values). The largest and smallest observed values that are not extreme values are also shown (whiskers).](bcr745-1){#F1}

![Receiver operating characteristic curve of **(a)**vascular endothelial growth factor and **(b)**basic fibroblast growth factor serum levels. CI, confidence interval.](bcr745-2){#F2}

###### 

Tumor and serum vascular endothelial growth factor (VEGF) in relation to clinical, pathological and biological characteristics in breast cancer patients

                   Tumor VEGF   Serum VEGF                                       
  ---------------- ------------ -------------- ------ ---- --------------------- -------
  Age                                                                            
   51--70 years    40           65 (10--100)   0.91   43   180.5 (30.8--768.4)   0.11
   \> 70 years     22           65 (5--100)           26   241.5 (22.7--953.5)   
  Histotype                                                                      
   Ductal          53           70 (5--100)           56   189.9 (30.8--953.5)   0.71
   Others          9            50 (10--75)           13   238.4 (22.7--456.8)   
  Tumor size                                                                     
   ≤ 2 cm          42           70 (10--100)   0.09   49   193.6 (30.8--953.5)   0.42
   \> 2 cm         20           47.5 (5--90)          19   144.5 (22.7--561.0)   
  Node status                                                                    
   Node-negative   30           70 (15--95)    0.22   34   204.4 (36.6--768.4)   0.50
   Node-positive   27           60 (5--100)           25   144.5 (22.7--953.5)   
  Grade                                                                          
   1--2            38           75 (10--100)   0.05   40   183.7 (30.8--768.4)   0.348
   3               11           35 (5--90)            11   144.5 (36.3--953.5)   
  Steroid status                                                                 
   ER-positive     43           70 (10--95)    0.05   47   187.0 (30.8--953.5)   0.45
   ER-negative     10           30 (5--90)            10   270.8 (48.3--768.4)   
   PgR-positive    31           65 (10--95)    0.72   34   187.1 (30.8--953.5)   0.70
   PgR-negative    22           67.5 (5--95)          23   193.6 (48.3--674.1)   

ER, estrogen receptor; PgR, progesterone receptor.

###### 

Tumor and serum basic fibroblast growth factor (bFGF) in relation to clinical, pathological and biological characteristics in breast cancer patients

                   Tumor bFGF   Serum bFGF                                    
  ---------------- ------------ --------------- ------ ---- ----------------- ------
  Age                                                                         
   51--70 years    41           45 (0--90)      0.25   46   2.2 (0.3--15.1)   0.40
   \> 70 years     22           65 (5--100)            27   3.0 (0.4--26.6)   
  Histotype                                                                   
   Ductal          54           55 (0--100)     0.68   60   2.2 (0.3--26.6)   0.90
   Others          9            60 (0--85)             13   2.3 (0.4--5.2)    
  Tumor size                                                                  
   ≤ 2 cm          43           55 (5--100)     0.53   51   2.3 (0.3--26.6)   0.37
   \> 2 cm         20           63 (5--100)            21   1.9 (0.4--11.1)   
  Node status                                                                 
   Node-negative   30           63 (0--100)     0.69   35   2.5 (0.3--15.1)   0.43
   Node-positive   27           65 (0--100)            28   2.0 (0.5--26.6)   
  Grade                                                                       
   1--2            38           62.5 (0--100)   0.99   42   2.3 (0.3--15.1)   0.57
   3               12           60 (5--100)            13   3.1 (1.5--26.6)   
  Steroid status                                                              
   ER-positive     43           45 (0--100)     0.43   49   2.2 (0.3--15.1)   0.32
   ER-negative     10           65 (5--95)             11   3.5 (1.8--11.1)   
   PgR-positive    32           38 (0--100)     0.12   35   2.0 (0.4--8.6)    0.19
   PgR-negative    21           70 (5--95)             25   2.5 (0.3--15.1)   

ER, estrogen receptor; PgR, progesterone receptor.

###### 

Correlation between serum and tumor vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF)

                                 *r*~s~   *P*
  ------------------------------ -------- -------
  Tumor VEGF versus tumor bFGF   0.420    0.001
  Serum VEGF versus serum bFGF   0.200    0.038
  Serum VEGF versus tumor VEGF   0.133    0.320
  Serum bFGF versus tumor bFGF   0.037    0.775

*r*~s~, Spearman\'s correlation coefficient.

###### 

Basic fibroblast growth factor sensitivity and specificity in women older than 50 years of age\*

                     Number of cases/controls   Sensitivity (%)             Specificity (%)
  ------------------ -------------------------- --------------------------- ----------------------------
  Overall series     73/65                      84.9 (95% CI, 76.7--93.1)   63.1 (95% CI, 51.4--74.8)
  51--70 years old   46/51                      76.1 (95% CI, 63.8--88.4)   64.7 (95% CI, 51.6--77.8)
  \> 70 years old    27/14                      77.8 (95% CI, 62.1--93.5)   78.6 (95% CI, 57.1--100.0)

CI, confidence interval. \* Cut-off value, 1.00 pg/ml.
